Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash. Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA therapeutics for use in Covid-19 and many other indications.
Read the full article: Merck to Acquire Exelead //
Source: https://www.prnewswire.com/news-releases/definitive-agreement-to-acquire-exelead-will-strengthen-the-cdmo-offering-for-mrna-of-the-life-science-business-of-merck-kgaa-darmstadt-germany-301455476.html